Charles Schwab Investment Management Inc Lyra Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 111,609 shares of LYRA stock, worth $21,205. This represents 0.0% of its overall portfolio holdings.
Number of Shares
111,609
Previous 111,609
-0.0%
Holding current value
$21,205
Previous $29,000
20.69%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding LYRA
# of Institutions
59Shares Held
32MCall Options Held
21.1KPut Options Held
400-
Perceptive Advisors LLC New York, NY12.8MShares$2.42 Million0.09% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.77MShares$906,8350.0% of portfolio
-
Black Rock Inc. New York, NY2.83MShares$537,6950.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.78MShares$528,2490.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.78MShares$338,0590.0% of portfolio
About Lyra Therapeutics, Inc.
- Ticker LYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,826,400
- Market Cap $6.05M
- Description
- Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...